Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2026)

Arcus Biosciences' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 200.0% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $18.0 million (up 157.14% YoY), while the FY2025 annual figure was $24.0 million, up 700.0% from the prior year.
• Change in Account Payables was -$3.0 million for Q1 2026 at Arcus Biosciences, down from $13.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $13.0 million in Q3 2025 to a low of -$19.0 million in Q2 2023.
• Historically, Change in Account Payables has averaged $2.1 million across 5 years, with a median of $4.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables surged 1786.79% in 2022, then sank 575.0% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $8.0 million in 2022, then tumbled by 75.0% to $2.0 million in 2023, then jumped by 150.0% to $5.0 million in 2024, then surged by 160.0% to $13.0 million in 2025, then slumped by 123.08% to -$3.0 million in 2026.
• The last three Change in Account Payables figures came in at -$3.0 million (Q1 2026), $13.0 million (Q3 2025), and $8.0 million (Q2 2025), per Business Quant data.